Greenstreet Yvonne's Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Oct 3, 2025
- Accession no.
- 0001735276-25-000116
- Filed
- Oct 3, 2025
- Trade date
- Oct 1-2, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 14 non-derivative transactions and 0 derivative transactions. Open-market sales total $4.03M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Greenstreet YvonneCIK 0001446125 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2025 | Common Stock | AGrant or awardAcquired | +3,860 | $0.00 | $0 | 60,081 | Direct | |
| Oct 1, 2025 | Common Stock | AGrant or awardAcquired | +14,252 | $0.00 | $0 | 74,333 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −350 | $446.53 | −$156,285.5 | 73,983 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −171 | $447.92 | −$76,594.32 | 73,812 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −548 | $448.77 | −$245,925.96 | 73,264 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −758 | $449.79 | −$340,940.82 | 72,506 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −1,642 | $450.81 | −$740,230.02 | 70,864 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −1,010 | $451.86 | −$456,378.6 | 69,854 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −2,029 | $452.69 | −$918,508.01 | 67,825 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −999 | $453.77 | −$453,316.23 | 66,826 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −741 | $454.84 | −$337,036.44 | 66,085 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −221 | $455.82 | −$100,736.22 | 65,864 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −446 | $457.43 | −$204,013.78 | 65,418 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −9 | $457.64 | −$4,118.76 | 65,409 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.